Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation.
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Groups of five male and five female beagle dogs were fed diets containing the phenylurea and the pyrimidone components (purity unspecified) in a ratio of 3:1 on six days per week for two years. The actual intakes were 0, 60, 180, or 600 mg/kg bw/day of the phenylurea component and 0, 20, 60, or 200 mg/kg bw/day of the pyrimidone component. Two animals of each sex per group were killed after one year. Clinical observations were made daily, and body weight, food consumption, and reflexes were determined weekly; water intake and urinary output were measured monthly. Hematological, clinical chemical, and urinary parameters were determined before treatment and in months 3, 6, 12, 18, and 24. A wide range of tissues from all dogs was examined grossly and microscopically. ...No abnormal behavior or physical signs were seen; however, one male at the intermediate dose died of unknown causes during week 44. A green-to-yellowish hue was seen in the excreta of all treated dogs. Body-weight gain, food intake, and hematological and urinary parameters were unaffected by treatment. Serum alanine aminotransferase activity was increased in several dogs at the highest dose and in one dog at each of the lower doses, but in most cases the effects were transitory. The highest values were observed at about 12 months, and elevated activity persisted in only two animals at the high dose. Organ weights and gross pathological appearance revealed no treatment-related changes. The histopathological appearance was unremarkable, apart from slight bile-duct proliferation in one dog killed after one year of treatment with the high dose. This animal had been found to have elevated serum alanine aminotransferase activity. Although the relationship between the hepatic findings and treatment was unclear, the conservative NOEL in this study is 240 mg/kg bw day.
/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Groups of FDRL rats were fed diets containing the phenylurea and the pyrimidone components (purity unspecified) for two years at concentrations calculated to give doses of 0, 50, 150, or 300 mg/kg bw/day of the phenylurea component and 0, 17, 50, or 100 mg/kg bw/day of the pyrimidone component. The groups consisted of 50 males and 50 females for control and the high doses and 40 males and 40 females for the low and intermediate doses. Five rats of each sex from the control and high-dose groups were killed during months 6 and 18, and 10 rats of each sex per group were killed in week 56. The animals were observed daily for behavior, physical appearance, and survival. Food consumption and the efficiency of food use were assessed weekly for the first 12 weeks and then periodically on 15 animals of each sex per group. Body weight was recorded weekly for the first 12 weeks, then biweekly until week 26 and monthly thereafter. Water intake and urinary output were measured on 10 rats of each sex per group during one week per month for the first three months. Limited hematological, clinical chemical and urinary parameters were examined on 10 rats of each sex per group at 3, 6, 9, 12, 18, and 24 months. A wide range of tissues from all rats was examined grossly and microscopically. ...No abnormal behavior was noted, and mortality was unaffected by treatment. Food and water intake and body-weight gain were similar in all groups. There were no treatment-related effects on hemoglobin, hematocrit, leukocytes, blood urea nitrogen, serum alanine aminotransferase activity, blood glucose, urinary parameters, organ weights, or gross pathological appearance. Changes in the kidney, such as calcareous material in the tubules, calcification in the renal pelvis, tubules, glomeruli, or medulla, and calculi, were more frequent in treated groups at 56 weeks, but the overall incidence was similar in all groups at the end of the study. The incidence of testicular atrophy was slightly elevated in some treated males at 104 weeks, but significance was not attained. Tumor incidences were unaffected. The NOEL was 400 mg/kg bw/day of the 3:1 mixture.
Rats received single oral doses of 1, 5, or 10 mg/kg bw nicarbazin; one animal at each dose was killed 6 or 18 hr after treatment, and the blood concentrations of the phenylurea and pyrimidone components were determined. Low concentrations of the phenylurea component were detected at 6 hr, but it was not detected at 18 hr. The pyrimidone component was found at considerably higher concentrations, which increased between 6 and 18 hr. Qualitatively similar findings were obtained in rats given oral doses of 0.1, 1, or 5 mg/kg bw per day for eight days and killed 4 or 24 hr after the last dose. The blood concentrations of the pyrimidone component were dose-related, while those of the phenylurea component showed a flat response. In the latter experiment, urine collected for 5 hr after the last dose contained dose-related concentrations of each component of nicarbazin, although the concentrations of the pyrimidone were an order of magnitude higher than those of the phenylurea component
...Nicarbazin, in the form of 4,4'-dinitrocarbanilide (DNC), was detected in 39 of the 190 eggs analysed. ... The concentrations of both the DNC and 4,6-dimethyl-2-hydroxypyrimidine (DHP) components of the drug in eggs were proportional to feed levels. The maximum feed nicarbazin concentration of 12.1 mg/kg (8.6 mg/kg DNC and 3.5 mg/kg DHP) gave rise to mean maximum whole egg concentrations of 631 micrograms/kg DNC and 51.8 micrograms/kg DHP. After withdrawal of the experimental diet, DNC was undetectable in eggs after 12 days and DHP after 3 days. Feed contaminated with nicarbazin at concentrations greater than about 2 mg/kg gave rise to egg DNC residues at concentrations greater than the Differential Action Limit (DAL) set by the UK (100 micrograms/kg). DNC was contained almost entirely in the yolk of the egg, whereas DHP was distributed between albumen and yolk in a ratio of approximately 3:1.
Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE Product identifiers Product name : Nicarbazin CAS-No. : 330-95-0 Relevant identified uses of the substance or mixture and uses advised against Identified uses : Laboratory chemicals, Manufacture of substances Section 2. HAZARDS IDENTIFICATION Classification of the substance or mixture Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP] Skin irritation (Category 2) Eye irritation (Category 2) Specific target organ toxicity - single exposure (Category 3) Classification according to EU Directives 67/548/EEC or 1999/45/EC Irritating to eyes, respiratory system and skin. Label elements Labelling according Regulation (EC) No 1272/2008 [CLP] Pictogram Signal word Warning Hazard statement(s) H315 Causes skin irritation. H319 Causes serious eye irritation. H335 May cause respiratory irritation. Precautionary statement(s) P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Supplemental Hazard none Statements According to European Directive 67/548/EEC as amended. Hazard symbol(s) R-phrase(s) R36/37/38 Irritating to eyes, respiratory system and skin. S-phrase(s) S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 Wear suitable protective clothing. Other hazards - none Section 3. COMPOSITION/INFORMATION ON INGREDIENTS Substances : N,N′-bis(4-Nitrophenyl)urea compound with 4,6-dimethyl-2-pyrimidinone Synonyms Formula : C13H10N4O5 · C6H8N2O Molecular Weight : 426,38 g/mol Component Concentration 1,3-Bis(4-nitrophenyl)urea--4,6-dimethylpyrimidin-2-ol (1:1) CAS-No. 330-95-0 - EC-No. 206-359-1 Section 4. FIRST AID MEASURES Description of first aid measures General advice Consult a physician. Show this safety data sheet to the doctor in attendance. If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. In case of skin contact Wash off with soap and plenty of water. Consult a physician. In case of eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. Most important symptoms and effects, both acute and delayed To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Indication of any immediate medical attention and special treatment needed no data available Section 5. FIREFIGHTING MEASURES Extinguishing media Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Special hazards arising from the substance or mixture Carbon oxides, nitrogen oxides (NOx) Advice for firefighters Wear self contained breathing apparatus for fire fighting if necessary. Further information no data available Section 6. ACCIDENTAL RELEASE MEASURES Personal precautions, protective equipment and emergency procedures Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. Environmental precautions Do not let product enter drains. Methods and materials for containment and cleaning up Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal. Reference to other sections For disposal see section 13. Section 7. HANDLING AND STORAGE Precautions for safe handling Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire protection. Conditions for safe storage, including any incompatibilities Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Specific end uses no data available Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION Control parameters Components with workplace control parameters Exposure controls Appropriate engineering controls Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday. Personal protective equipment Eye/face protection Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin protection Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Body Protection impervious clothing, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Respiratory protection For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Section 9. PHYSICAL AND CHEMICAL PROPERTIES Information on basic physical and chemical properties a) Appearance Form: solid b) Odour no data available c) Odour Threshold no data available d) pH no data available e) Melting point/freezing no data available point f) Initial boiling point and no data available boiling range g) Flash point no data available h) Evaporation rate no data available i) Flammability (solid, gas) no data available j) Upper/lower no data available flammability or explosive limits k) Vapour pressure no data available l) Vapour density no data available m) Relative density no data available n) Water solubility no data available o) Partition coefficient: n- no data available octanol/water p) Autoignition no data available temperature q) Decomposition no data available temperature r) Viscosity no data available s) Explosive properties no data available t) Oxidizing properties no data available Other safety information no data available Section 10. STABILITY AND REACTIVITY Reactivity no data available Chemical stability no data available Possibility of hazardous reactions no data available Conditions to avoid no data available Incompatible materials Strong oxidizing agents Hazardous decomposition products Other decomposition products - no data available Section 11. TOXICOLOGICAL INFORMATION Information on toxicological effects Acute toxicity no data available Skin corrosion/irritation no data available Serious eye damage/eye irritation no data available Respiratory or skin sensitization no data available Germ cell mutagenicity no data available Carcinogenicity IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. Reproductive toxicity no data available Specific target organ toxicity - single exposure Inhalation - May cause respiratory irritation. Specific target organ toxicity - repeated exposure no data available Aspiration hazard no data available Potential health effects Inhalation May be harmful if inhaled. Causes respiratory tract irritation. Ingestion May be harmful if swallowed. Skin May be harmful if absorbed through skin. Causes skin irritation. Eyes Causes serious eye irritation. Signs and Symptoms of Exposure To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Additional Information RTECS: FE0900000 Section 12. ECOLOGICAL INFORMATION Toxicity no data available Persistence and degradability no data available Bioaccumulative potential no data available Mobility in soil no data available Results of PBT and vPvB assessment no data available Other adverse effects no data available Section 13. DISPOSAL CONSIDERATIONS Waste treatment methods Product Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Contaminated packaging Dispose of as unused product. Section 14. TRANSPORT INFORMATION UN number ADR/RID: - IMDG: - IATA: - UN proper shipping name ADR/RID: Not dangerous goods IMDG: Not dangerous goods IATA: Not dangerous goods Transport hazard class(es) ADR/RID: - IMDG: - IATA: - Packaging group ADR/RID: - IMDG: - IATA: - Environmental hazards ADR/RID: no IMDG Marine pollutant: no IATA: no Special precautions for user no data available Section 15. REGULATORY INFORMATION This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006. Safety, health and environmental regulations/legislation specific for the substance or mixture no data available Chemical Safety Assessment no data available Section 16. OTHER INFORMATION Further information Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Corporation and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product. See and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.
INSECTICIDAL, MITICIDAL, NEMATICIDAL, MOLLUSCICIDAL, MICROBICIDAL, OR BACTERICIDAL COMPOSITION AND METHOD FOR CONTROLLING PEST
申请人：NISSAN CHEMICAL INDUSTRIES, LTD.
公开号：US20170135347A1
公开（公告）日：2017-05-18
The present invention provides a novel insecticidal, miticidal, nematicidal, microbicidal, or bactericidal composition and a novel pest control method. An insecticide, miticide, nematicide, molluscicide, disinfectant, or bactericide composition containing one or two substances selected from 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)isoxazole-3-yl]-2-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]benzamide or (Z)-4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazole-3-yl]-N-(methoxyiminomethyl)-2-methylbenzamide, and one or more substances selected from known insecticide, miticide, nematicide, molluscicide, disinfectant, or bactericide compounds.
Compounds described by the Formula (I) or (II): or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with one or more anticoccidieal agent(s). A composition for controlling coccidiosis in poultry comprises the compound alone, or in combination with one or more anticoccidial agent(s). Methods for the treatment and prevention of mammalian protozoal diseases, such as, for example, toxoplasmosis, malaria. African typanosomiasis, Chagas disease, and opportunistic infections comprise administering the compound alone, or in combination with one or more antiprotozoal agent(s).
FLUOROETHYL THIAMINE OR SALTS THEREOF AND APPLICATION THEREOF IN PREPARATION OF ANTICOCCIDIAL DRUGS
申请人：GUANGZHOU ORIGMOL FEED-ADDITIVE CO., LTD
公开号：US20150133480A1
公开（公告）日：2015-05-14
The present invention discloses a fluoroethyl thiamine or salts thereof and application thereof in preparation of anticoccidial drugs. The structural formula of the fluoroethyl thiamine or salts thereof is shown as Formula (I). The fluoroethyl thiamine or salts thereof of the present invention have a remarkable anticoccidial effect, particularly on some coccidia which had resistance to other anticoccidial drugs, therefore the fluoroethyl thiamine or salts thereof of the present invention can be applied to preparation of anticoccidial drugs. Thus, the present invention provides conditions for development of new anticoccidial drugs.
Agent for controlling animal diseases caused by parasites
申请人：ISHIHARA SANGYO KAISHA LTD.
公开号：US20030100586A1
公开（公告）日：2003-05-29
The present invention provides an agent for controlling animal diseases caused by parasites, which contains, as an active ingredient, an imidazole compound represented by the formula (I):
1
wherein R
1
is a cyano group, R
2
is an alkyl group which may be substituted, or a phenyl group which may be substituted, R
3
is a chlorine atom, and R
4
is a dimethylamino group.
Monoclonal antibodies to 4,4'-dinitrocarbanilide and a method for analyzing for the drug nicarbazin
申请人：——
公开号：US20010039332A1
公开（公告）日：2001-11-08
Hybridoma cell lines have been generated which produce and secrete monoclonal antibodies which selectively bind to 4,4′-dinitrocarbanilide (DNC), the active agent of nicarbazin. These hybridomas may be obtained by using as an immunization agent or immunogen, p-nitroaniline which has been conjugated to an immunogenic carrier. DNC in biological samples may be detected and quantified by contacting the sample with the antibodies to form a DNC/antibody immunocomplex when DNC is present, which immunocomplex may then be detected. The monoclonal antibodies also may be incorporated into kits for the detection and quantification of DNC and/or nicarbazin.
